[
  {
    "ts": "2025-10-19T04:13:22+00:00",
    "headline": "Assessing Bio-Techne Shares After a 20% Surge and New Therapeutics Collaboration in 2025",
    "summary": "If you’re weighing your next move with Bio-Techne stock, you’re certainly not alone. After a bumpy stretch over the past year, the stock is making its way back on investors’ watchlists, and for good reason. In just the last month, Bio-Techne shares have climbed an impressive 20.1%, which suggests that something is shifting in how the market views this mid-cap life sciences company. Although the year-to-date return remains in negative territory at -13.5%, that recent surge hints at fresh...",
    "url": "https://finance.yahoo.com/news/assessing-bio-techne-shares-20-041322605.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "cbf111f3-18f0-3a52-bb49-4ac7e16e886a",
      "content": {
        "id": "cbf111f3-18f0-3a52-bb49-4ac7e16e886a",
        "contentType": "STORY",
        "title": "Assessing Bio-Techne Shares After a 20% Surge and New Therapeutics Collaboration in 2025",
        "description": "",
        "summary": "If you’re weighing your next move with Bio-Techne stock, you’re certainly not alone. After a bumpy stretch over the past year, the stock is making its way back on investors’ watchlists, and for good reason. In just the last month, Bio-Techne shares have climbed an impressive 20.1%, which suggests that something is shifting in how the market views this mid-cap life sciences company. Although the year-to-date return remains in negative territory at -13.5%, that recent surge hints at fresh...",
        "pubDate": "2025-10-19T04:13:22Z",
        "displayTime": "2025-10-19T04:13:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ih9Jyeb4E8RAOq22ZtFHA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5jgPUxQrxmcesBmGBKgkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-bio-techne-shares-20-041322605.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-bio-techne-shares-20-041322605.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]